FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394498> ?p ?o ?g. }

• W4308394498 abstract "<h3>Background</h3> Data from prospective phase 3 trials of anti-PD-1 and anti-CTLA-4 demonstrate durable clinical benefit even in patients who discontinue ICI due to treatment related adverse events. However, outcomes for patients treated with anti-PD-1 therapy alone or with chemotherapy who discontinue treatment due to immune toxicities is unknown. <h3>Methods</h3> We retrospectively evaluated patients with stage IV NSCLC treated with first line ICI alone or with platinum-based chemotherapy at a tertiary cancer center between 2017 and 2021. Overall survival (OS) was calculated from the date of ICI treatment initiation to death from any cause or date of last follow-up. Patients still alive were censored at last follow-up. Overall survival was estimated using Kaplan-Meier method. <h3>Results</h3> 225 patients were identified and included, mean age 63.5 years, 57% were male, 91% former/current smokers, 17% squamous histology. ICI type was anti-PD-1 alone in 43%, ICI+chemotherapy in 56%, and ICI+ICI in 1%. 42 out of 225 patients had treatment held either temporarily or permanently for irAE (42/225, 19%, table 1). Of these patients, 19 were permanently discontinued from irAE and 22 were resumed on ICI (1 missing due to lost follow up). There was no difference in patient age, race, sex, smoking status, histology, or ICI type among patients with irAE and permanent ICI discontinuation vs not (table 2), however permanent discontinuation was more common in treatment with ICI monotherapy (60% vs 37% in ICI+Chemo vs 0% in ICI+ICI), but not statistically significant (p=0.13). Among all patients with any irAE treatment interruption, the median overall survival (mOS) was 54.1 months (95% CI 26.9, NR). There was no significant difference in mOS among patients who permanently discontinued ICI: 26.9 months (95% CI 3.3, NR) vs 22.8 months (95% CI 16.3, 28.1) for all other patients, p=0.84 (figure 1). Among patients with treatment interruption for irAE, there was no significant difference in mOS among those who resumed treatment vs those who permanently discontinued, though this may have been limited by sample size: 54.1 months (95% CI 26.9, NR) vs 26.9 months (95% CI 3.3, NR) (p=0.07, figure 2). <h3>Conclusions</h3> We observed no significant difference in mOS between patients with treatment interruption or discontinuation due to irAE. There appeared to be longer OS in patients who resumed treatment, though this was nonsignificant and likely limited by small sample size. These findings are consistent with continued clinical benefits despite treatment discontinuation in patients treated with first line ICI alone or with chemotherapy. <h3>Ethics Approval</h3> The study was approved by the OSU Institutional Ethics Board" @default.
• W4308394498 created "2022-11-11" @default.
• W4308394498 creator A5004712121 @default.
• W4308394498 creator A5006468163 @default.
• W4308394498 creator A5006493659 @default.
• W4308394498 creator A5009372853 @default.
• W4308394498 creator A5014357050 @default.
• W4308394498 creator A5020594501 @default.
• W4308394498 creator A5030801209 @default.
• W4308394498 creator A5031691358 @default.
• W4308394498 creator A5035319531 @default.
• W4308394498 creator A5041806016 @default.
• W4308394498 creator A5049098969 @default.
• W4308394498 creator A5059048943 @default.
• W4308394498 creator A5059652753 @default.
• W4308394498 creator A5059895822 @default.
• W4308394498 creator A5063141833 @default.
• W4308394498 creator A5074431040 @default.
• W4308394498 creator A5079716545 @default.
• W4308394498 creator A5084710012 @default.
• W4308394498 creator A5090253314 @default.
• W4308394498 creator A5090780152 @default.
• W4308394498 creator A5091280788 @default.
• W4308394498 creator A5043538122 @default.
• W4308394498 date "2022-11-01" @default.
• W4308394498 modified "2023-10-04" @default.
• W4308394498 title "1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI)" @default.
• W4308394498 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1249" @default.
• W4308394498 hasPublicationYear "2022" @default.
• W4308394498 type Work @default.
• W4308394498 citedByCount "0" @default.
• W4308394498 crossrefType "proceedings-article" @default.
• W4308394498 hasAuthorship W4308394498A5004712121 @default.
• W4308394498 hasAuthorship W4308394498A5006468163 @default.
• W4308394498 hasAuthorship W4308394498A5006493659 @default.
• W4308394498 hasAuthorship W4308394498A5009372853 @default.
• W4308394498 hasAuthorship W4308394498A5014357050 @default.
• W4308394498 hasAuthorship W4308394498A5020594501 @default.
• W4308394498 hasAuthorship W4308394498A5030801209 @default.
• W4308394498 hasAuthorship W4308394498A5031691358 @default.
• W4308394498 hasAuthorship W4308394498A5035319531 @default.
• W4308394498 hasAuthorship W4308394498A5041806016 @default.
• W4308394498 hasAuthorship W4308394498A5043538122 @default.
• W4308394498 hasAuthorship W4308394498A5049098969 @default.
• W4308394498 hasAuthorship W4308394498A5059048943 @default.
• W4308394498 hasAuthorship W4308394498A5059652753 @default.
• W4308394498 hasAuthorship W4308394498A5059895822 @default.
• W4308394498 hasAuthorship W4308394498A5063141833 @default.
• W4308394498 hasAuthorship W4308394498A5074431040 @default.
• W4308394498 hasAuthorship W4308394498A5079716545 @default.
• W4308394498 hasAuthorship W4308394498A5084710012 @default.
• W4308394498 hasAuthorship W4308394498A5090253314 @default.
• W4308394498 hasAuthorship W4308394498A5090780152 @default.
• W4308394498 hasAuthorship W4308394498A5091280788 @default.
• W4308394498 hasBestOaLocation W43083944981 @default.
• W4308394498 hasConcept C121608353 @default.
• W4308394498 hasConcept C126322002 @default.
• W4308394498 hasConcept C141071460 @default.
• W4308394498 hasConcept C143998085 @default.
• W4308394498 hasConcept C197934379 @default.
• W4308394498 hasConcept C2776256026 @default.
• W4308394498 hasConcept C2776694085 @default.
• W4308394498 hasConcept C2778715236 @default.
• W4308394498 hasConcept C71924100 @default.
• W4308394498 hasConcept C90924648 @default.
• W4308394498 hasConceptScore W4308394498C121608353 @default.
• W4308394498 hasConceptScore W4308394498C126322002 @default.
• W4308394498 hasConceptScore W4308394498C141071460 @default.
• W4308394498 hasConceptScore W4308394498C143998085 @default.
• W4308394498 hasConceptScore W4308394498C197934379 @default.
• W4308394498 hasConceptScore W4308394498C2776256026 @default.
• W4308394498 hasConceptScore W4308394498C2776694085 @default.
• W4308394498 hasConceptScore W4308394498C2778715236 @default.
• W4308394498 hasConceptScore W4308394498C71924100 @default.
• W4308394498 hasConceptScore W4308394498C90924648 @default.
• W4308394498 hasLocation W43083944981 @default.
• W4308394498 hasOpenAccess W4308394498 @default.
• W4308394498 hasPrimaryLocation W43083944981 @default.
• W4308394498 hasRelatedWork W2055244776 @default.
• W4308394498 hasRelatedWork W2348529436 @default.
• W4308394498 hasRelatedWork W2358450743 @default.
• W4308394498 hasRelatedWork W2364910080 @default.
• W4308394498 hasRelatedWork W2375646327 @default.
• W4308394498 hasRelatedWork W2381460883 @default.
• W4308394498 hasRelatedWork W2407189953 @default.
• W4308394498 hasRelatedWork W2413020017 @default.
• W4308394498 hasRelatedWork W2480785262 @default.
• W4308394498 hasRelatedWork W2987628800 @default.
• W4308394498 isParatext "false" @default.
• W4308394498 isRetracted "false" @default.
• W4308394498 workType "article" @default.